Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.52 |
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | CA9 | Q16790 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861514 | 0.86 | CYP3A4 (0.58) | CA1CA2CA9ALDH1A1CYP3A4 | |
| SCHEMBL612619 | 0.80 | CA1 (0.48) | CA1CA2CA9TTR | |
| SCHEMBL14318817 | 0.79 | CYP3A4 (0.65) | CA1CA2CA9ALDH1A1CYP3A4 | |
| SCHEMBL2766389 | 0.79 | CA1 (0.52) | CA1CA2CA9ALDH1A1CYP3A4 | |
| SCHEMBL27837240 | 0.79 | CYP3A4 (0.43) | CA1CA2CA9ALDH1A1CYP3A4 | |
| SCHEMBL24929461 | 0.75 | CA1 (0.48) | CA1CA2CA9ALDH1A1CYP3A4 | |
| SCHEMBL2002230 | 0.75 | CD44 (0.41) | CA1CA2CA9ALDH1A1CYP3A4 | |
| SCHEMBL3825968 | 0.75 | CA1 (0.48) | CA1CA2CA9ALDH1A1CYP3A4 | |
| SCHEMBL20670572 | 0.75 | CA1 (0.48) | CA1CA2CA9ALDH1A1CYP3A4 | |
| SCHEMBL15286761 | 0.75 | CA1 (0.48) | CA1CA2CA9ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298081-A1 | CONDENSED HETEROCYCLIC COMPOUND | KASUMA PARTNERS INC. (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170298081-A1 | CONDENSED HETEROCYCLIC COMPOUND | KASUMA PARTNERS INC. (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-3178810-A1 | CONDENSED HETEROCYCLIC COMPOUND | Kasuma Partners Inc. (JP) | 2017-06-14 | — | — | EP | disclosed |
| EP-3178810-A1 | CONDENSED HETEROCYCLIC COMPOUND | Kasuma Partners Inc. (JP) | 2017-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298081-A1 | CONDENSED HETEROCYCLIC COMPOUND | APOB, NPC1, NPC1L1 | CA1 3316/4885CA2 1894/4885CA9 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.